AnaptysBio (LTS:0HFQ) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HFQ AnaptysBio Inc LTS:0HFQ
58 GF Score
Price $54.60
GF Value $54.89
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is AnaptysBio SpecialCharges?

Special Charges only applies to banks.

LTS:0HFQ
58GF Score
AnaptysBio Inc LTS:0HFQ
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AnaptysBio (LTS:0HFQ) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be undervalued. The current stock price of $54.60 is trading 0.5% below its estimated GF Value™ of $54.89. GuruFocus considers AnaptysBio to be Fairly Valued.

Key valuation signals for LTS:0HFQ:

  • SpecialCharges:
  • GF Value™: $54.89 vs. price of $54.60 (0.5% below fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the LTS:0HFQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AnaptysBio Business Description

Other Exchanges ANAB:USAAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
58GF Score

Get the complete analysis for LTS:0HFQ

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.60
Price
$54.89
GF Value